Describe a single-center real-world experience with comprehensive genomic profiling (CGP) to identify genotype directed therapy (GDT) options for patients with malignancies refractory to standard treatment options. | Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy